192 related articles for article (PubMed ID: 12952292)
1. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma.
Mintz A; Gibo DM; Madhankumar AB; Debinski W
J Neurooncol; 2003; 64(1-2):117-23. PubMed ID: 12952292
[TBL] [Abstract][Full Text] [Related]
2. Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy.
Kawakami K; Kioi M; Liu Q; Kawakami M; Puri RK
J Immunother; 2005; 28(3):193-202. PubMed ID: 15838375
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.
Husain SR; Puri RK
J Neurooncol; 2003 Oct; 65(1):37-48. PubMed ID: 14649884
[TBL] [Abstract][Full Text] [Related]
4. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.
Kioi M; Husain SR; Croteau D; Kunwar S; Puri RK
Technol Cancer Res Treat; 2006 Jun; 5(3):239-50. PubMed ID: 16700620
[TBL] [Abstract][Full Text] [Related]
5. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
Kioi M; Kawakami K; Puri RK
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
[TBL] [Abstract][Full Text] [Related]
6. Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts.
Kawakami M; Kawakami K; Puri RK
Mol Cancer Ther; 2002 Oct; 1(12):999-1007. PubMed ID: 12481422
[TBL] [Abstract][Full Text] [Related]
7. Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease.
Kawakami K; Kawakami M; Puri RK
Mol Cancer Ther; 2004 Feb; 3(2):137-47. PubMed ID: 14985454
[TBL] [Abstract][Full Text] [Related]
8. Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells.
Han J; Yang L; Puri RK
J Neurooncol; 2005 Mar; 72(1):35-46. PubMed ID: 15803373
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
[TBL] [Abstract][Full Text] [Related]
10. Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors.
Kawakami M; Kawakami K; Takahashi S; Abe M; Puri RK
Cancer; 2004 Sep; 101(5):1036-42. PubMed ID: 15329913
[TBL] [Abstract][Full Text] [Related]
11. Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts.
Kawakami K; Husain SR; Bright RK; Puri RK
Cancer Gene Ther; 2001 Nov; 8(11):861-8. PubMed ID: 11773976
[TBL] [Abstract][Full Text] [Related]
12. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model.
Kawakami K; Kawakami M; Kioi M; Husain SR; Puri RK
J Neurosurg; 2004 Dec; 101(6):1004-11. PubMed ID: 15597761
[TBL] [Abstract][Full Text] [Related]
13. Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines.
Kawakami K; Kawakami M; Liu Q; Puri RK
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):230-7. PubMed ID: 16111594
[TBL] [Abstract][Full Text] [Related]
14. Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor alpha2 chain in vivo.
Kawakami K; Kawakami M; Husain SR; Puri RK
Gene Ther; 2003 Jul; 10(13):1116-28. PubMed ID: 12808442
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin.
Joshi BH; Kawakami K; Leland P; Puri RK
Clin Cancer Res; 2002 Jun; 8(6):1948-56. PubMed ID: 12060640
[TBL] [Abstract][Full Text] [Related]
16. Molecular targeting of malignant gliomas with novel multiply-mutated interleukin 13-based cytotoxins.
Nash KT; Thompson JP; Debinski W
Crit Rev Oncol Hematol; 2001; 39(1-2):87-98. PubMed ID: 11418305
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.
Kawakami K; Kawakami M; Joshi BH; Puri RK
Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072
[TBL] [Abstract][Full Text] [Related]
18. IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13.
Mintz A; Gibo DM; Slagle-Webb B; Christensen ND; Debinski W
Neoplasia; 2002; 4(5):388-99. PubMed ID: 12192597
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor alpha chain.
Kawakami K; Joshi BH; Puri RK
Hum Gene Ther; 2000 Sep; 11(13):1829-35. PubMed ID: 10986556
[TBL] [Abstract][Full Text] [Related]
20. Novel anti-brain tumor cytotoxins specific for cancer cells.
Debinski W; Gibo DM; Obiri NI; Kealiher A; Puri RK
Nat Biotechnol; 1998 May; 16(5):449-53. PubMed ID: 9592393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
